Targeting molecular therapy by Iressa® (ZD1839);Thérapies moléculaires ciblées: L'exemple de l'Iressa® (ZD1839)

Medecine/Sciences

Volumn 19, Issue 11, 2003, Pages 1052-1054

  Fayette, Jérome ^a   Soria, Jean Charles ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IRINOTECAN; PROTEIN TYROSINE KINASE;

COLORECTAL CANCER; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; NOTE; PROTEIN TARGETING;

EID: 0242666127     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/200319111052     Document Type: Note

References (13)

1. Baselga J, Albanell J. Targeting epidermal growth factor receptor in lung cancer. Curr Oncol Rep 2002; 4: 317-24.
2. Saltz L, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001; 20: 3a (abstract 7).
3. Kim ES, Mauer AM, Fossella FV, et al. A phase II study of Erbitux (IMC-C225), an epidermal growth factor receptor (EGFR) blocking antibody, in combination docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002; 21: 293a (abstract 1168)
4. Garcia de Palazzo IE, Adams GP, Sunderaresham P, et al. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res 1993; 53: 3217-20.
5. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine-kinase inhibitor. Clin Cancer Res 2000; 6: 2053-63.
6. Naruse I, Ohmori T, Ao Y, et al. Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZO1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo. Int J Cancer 2002; 98: 310-5.
7. Helfrich B, Phistry M, Chan D, et al. ZD1839 (Iressa), a selective EGFR-TKI enhances radiation and chemotherapy cytotoxicity in EGFR positive human non-small cell lung cancer cells (NSCLC) in vitro. Am Ass Cancer Res 2001; 2: 12-6.
8. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237-46.
9. Kris MG, Natale RB, Herbst RS, et al. A phase II trial of ZD1839 (Iressa) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL2). Proc Am Soc Clin Oncol 2002; 21: 292a (abstract 1166).
10. Giaccone G, Johnson D, Manegold C, et al. A phase III clinical trial of ZD1839 (Iressa) in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (INTACT1). Ann Oncol 2002; 13: 2 (abstract4).
11. Johnson D, Herbst R, Giaccone G, et al. ZD1839(Iressa) in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small cell lung cancer(NSCLC): results from a phase III trial (INTACT2). Ann Oncol 2002; 13: 127 (abstract 468).
12. Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003; 361: 137-9.
13. Gupta N, Ahmed I, Steinberg H, et al. Gemcitabine-induced pulmonary toxicity: case report and review of the literature. Am J Clin Oncol 2002; 25: 96-100.